Health Catalyst appoints Ben Albert as CEO, plans to reduce board size
Health Catalyst (NASDAQ:HCAT) has appointed Ben Albert as its new CEO and board member, effective February 12, 2026, succeeding Dan Burton. Albert, previously President and COO, joined the company through an acquisition and brings extensive healthcare leadership experience. The company also announced a reduction in its board size to five directors, with Justin Spencer elected as Board Chair, as part of strategic efforts to enhance operational depth and focus amidst its stock trading near a 52-week low.
Health Catalyst appoints Ben Albert as CEO
Health Catalyst (HCAT) has appointed Ben Albert as its new CEO and a member of its Board of Directors, effective February 12. Albert, previously President and COO, replaces Dan Burton, who will transition to a strategic advisor role. Albert's appointment follows his work to streamline the company's leadership and focus resources on key business priorities for improved financial performance.
Health Catalyst appoints Ben Albert as CEO, plans to reduce board size
Health Catalyst, Inc. (NASDAQ:HCAT) has appointed Ben Albert as its new CEO and board member, effective February 12, 2026, as the company's stock trades near its 52-week low. Albert, previously President and COO, takes over from Dan Burton and plans to leverage his extensive healthcare experience to improve clinical quality and strengthen consumer loyalty. Concurrently, the healthcare data company announced a reduction in its board size from nine to five directors, with Justin Spencer elected as the new Board Chair.
Health Catalyst Appoints Ben Albert as Chief Executive Officer
Health Catalyst (Nasdaq: HCAT) has appointed Ben Albert as its new Chief Executive Officer, effective February 12, 2026. Albert, previously the President and COO, will focus on improving cost and operational efficiency, clinical quality, and consumer experience. Former CEO Dan Burton has stepped down and will transition to a strategic advisor role, while the company's Board of Directors will be reduced to five members.
Health Catalyst (HCAT) to Release Earnings on Wednesday
Health Catalyst (NASDAQ:HCAT) is scheduled to release its Q4 2025 earnings before the market opens on Wednesday, February 25th, with analysts projecting earnings of $0.10 per share and revenue of $73.9880 million. The article also provides details on recent insider trading activities, institutional investor movements, and analyst ratings, alongside a company profile. The stock's price performance and key financial metrics are also outlined.
Zoom, Akamai Technologies, Health Catalyst, SentinelOne, and PubMatic Stocks Trade Down, What You Need To Know
A number of software stocks, including Zoom, Akamai Technologies, Health Catalyst, SentinelOne, and PubMatic, experienced a downturn due to investor fears that "agentic AI" tools could disrupt traditional Software-as-a-Service (SaaS) business models. This "AI Panic" led to a broad sell-off across the sector, although market overreactions can sometimes present buying opportunities for high-quality stocks. Health Catalyst, in particular, saw a significant drop, contributing to its year-to-date decline, amidst ongoing market volatility and shifting expectations for interest rate cuts from the Federal Reserve due to a strong U.S. jobs report.
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
Health Catalyst, Inc. (NASDAQ:HCAT) currently has a low price-to-sales (P/S) ratio of 0.4x, which is significantly below the industry average, primarily due to its sluggish past revenue growth and projected negative future revenue growth. Analysts forecast a 0.2% annual decline in revenue over the next three years, contrasting sharply with the industry's predicted 13% annual growth. This poor outlook leads to the low P/S ratio, making it difficult to foresee a substantial rise in the stock price without a material change in revenue performance.
Down 21.4% in 4 Weeks, Here's Why Health Catalyst (HCAT) Looks Ripe for a Turnaround
Health Catalyst (HCAT) stock has dropped 21.4% in the past four weeks but appears poised for a turnaround. This is indicated by its Relative Strength Index (RSI) of 28.93, suggesting it's oversold, and a significant 128.1% increase in consensus EPS estimates by analysts over the last 30 days. Additionally, HCAT holds a Zacks Rank #2 (Buy), further supporting the potential for a near-term rebound.
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
Health Catalyst, Inc. (NASDAQ:HCAT) has a low price-to-sales (P/S) ratio of 0.4x, which is significantly lower than the Healthcare Services industry average. This low P/S ratio is attributed to the company's sluggish revenue growth, with analysts forecasting a decline of 0.2% per annum over the next three years, contrasting sharply with the industry's projected 13% annual growth. The article suggests that improved revenues are necessary for the company's shares to perform better.
Health Catalyst and F5 Stocks Trade Down, What You Need To Know
Health Catalyst (HCAT) and F5 (FFIV) stocks traded down following a broad market sell-off, driven by investor selectivity in the AI boom and dampened expectations for near-term interest rate cuts. A stronger-than-expected U.S. jobs report pushed back anticipated Fed rate cuts to July, negatively impacting growth-oriented sectors like software due to higher interest rates. Health Catalyst, in particular, saw its shares fall by 6.8% and is down 18.9% year-to-date, trading significantly below its 52-week high.
Health Catalyst, Inc (HCAT) Stock Analysis: Exploring A Potential Upside Of Nearly 95%
Health Catalyst, Inc (HCAT) is a healthcare data and analytics company with a current stock price of $1.99 and a market capitalization of $140.75 million. Despite recent volatility and unprofitability, the stock is oversold with a positive free cash flow, and analysts project a potential upside of nearly 95% to a consensus target price of $3.88. The company's Ignite platform and expertise solutions position it to capitalize on demand for data-driven healthcare solutions, making it an intriguing option for growth-seeking investors.
Health Catalyst leverages AI to enhance clinical outcomes
Health Catalyst emphasizes that AI-driven, near-real-time data analytics are crucial for improving clinical outcomes, moving beyond just raw data. Leaders from the company highlighted this approach in a recent video and article on Healthcare IT Today. This strategy aims to provide clinicians with actionable insights, thereby advancing patient care effectively.
Why Health Catalyst (HCAT) Stock Is Trading Lower Today
Shares of Health Catalyst (HCAT) fell by 8.4% due to investor fears regarding artificial intelligence disruption, leading to a broad-based sell-off in the healthcare data analytics sector. This "basket-style reaction" affected the S&P 500 Information Technology Sector and the Magnificent Seven stocks. The movement suggests that while the market sees the news as meaningful, it doesn't fundamentally alter its perception of Health Catalyst's business despite the stock's year-to-date decline and significant drop from its 52-week high.
How Health Catalyst Turns Analytics Into Action Clinicians Actually Use
Health Catalyst helps healthcare organizations move beyond traditional analytics to drive actual clinical improvement by providing near-real-time data, using AI to prioritize effective interventions, and fostering clinician ownership of solutions. This approach enables faster feedback, targeted actions, and sustainable change, turning analytics into a tool that directly influences patient care outcomes. The company emphasizes that lasting improvements come from clinicians designing solutions they trust, supported by data that confirms their impact.
Health Catalyst, Inc (HCAT) Stock Analysis: Exploring a Compelling 76.94% Upside Potential
Health Catalyst, Inc. (HCAT) is an attention-grabbing stock in the Health Information Services sector, with analysts projecting a 76.94% upside potential. Despite current financial challenges like negative EPS and ROE, the company showcases a positive free cash flow and a strategic position in the healthcare data analytics market. This analysis suggests HCAT could be a rewarding investment as it focuses on technology advancements and addresses its financial hurdles.
Here's Why Health Catalyst (HCAT) Is a Great 'Buy the Bottom' Stock Now
Health Catalyst (HCAT) shows signs of a potential trend reversal, indicated by a hammer chart pattern after a recent 7.5% decline. This technical signal, combined with a significant 125% increase in consensus EPS estimates over the last 30 days and a Zacks Rank #2 (Buy), suggests growing optimism among analysts and strong fundamental prospects. These factors point to HCAT as a potential "buy the bottom" opportunity for investors.
Navigating 2026: How health systems can thrive amid AI, labor and consumer pressures
This article discusses the challenges and opportunities for health systems in 2026, focusing on the impact of AI, labor shortages, and evolving consumer demands. It highlights strategies for healthcare providers to navigate these pressures and succeed in a rapidly changing environment. The content also touches on related healthcare news, including Medicare Advantage changes, hospital immigration enforcement, medical device advancements, and AI in prescription services.
Health Catalyst Announces Chief Commercial Officer Transition Plan
Health Catalyst (HCAT) announced that its Chief Commercial Officer, Kevin Freeman, will transition out of his role on February 1, 2026, and move into a senior advisor position to maintain continuity and leverage his expertise. Despite this strategic move and some positive financial insights, TipRanks' AI Analyst, Spark, rates HCAT as Neutral due to ongoing financial performance challenges and week technical analysis and valuation. The stock currently has a Hold rating from analysts with a $2.00 price target.
Health Catalyst, MongoDB, Asana, Domo, and RingCentral Stocks Trade Up, What You Need To Know
Several tech stocks, including Health Catalyst, MongoDB, Asana, Domo, and RingCentral, saw significant jumps in the afternoon trading session. This rally was reportedly triggered by easing geopolitical tensions in Greenland, which boosted overall investor sentiment and led to a rebound in major indices like the S&P 500 and Nasdaq Composite. The article also provides a specific look into Domo's recent volatility and a previous gain due to a partnership with Yamaha Corporation.
Health Catalyst, MongoDB, Asana, Domo, and RingCentral Stocks Trade Up, What You Need To Know
Several tech stocks, including Health Catalyst, MongoDB, Asana, Domo, and RingCentral, saw increases following reports of easing geopolitical tensions in Greenland, which boosted overall investor sentiment. This relief rally led to a broader market upswing, with major indices rebounding as investors re-entered riskier assets. The article also highlights Domo's recent volatility and its partnership with Yamaha Corporation, which is leveraging Domo's AI and Data Products platform for logistics operations.
Health Catalyst, MongoDB, Asana, Domo, and RingCentral Stocks Trade Up, What You Need To Know
Several tech stocks, including Health Catalyst, MongoDB, Asana, Domo, and RingCentral, saw significant jumps in trading following reports of easing geopolitical tensions in Greenland. This broader market rally, which also benefited the S&P 500 and Nasdaq Composite, indicates a return to riskier assets as market uncertainty decreased. Domo's individual surge was also partly attributed to a recent announcement regarding Yamaha Corporation's adoption of its AI and Data Products platform for global logistics, leading to operational efficiencies.
Q3 Earnings Highs And Lows: Health Catalyst (NASDAQ:HCAT) Vs The Rest Of The Data Analytics Stocks
This article analyzes the Q3 earnings of Health Catalyst (HCAT) and other data analytics companies, highlighting their performance against analyst expectations. While the sector as a whole saw strong revenue beats, share prices have generally declined. Health Catalyst had a slower quarter despite exceeding revenue estimates, while Strategy (MSTR) delivered the best Q3 performance despite a subsequent stock drop.
Q3 Earnings Highs And Lows: Health Catalyst (NASDAQ:HCAT) Vs The Rest Of The Data Analytics Stocks
This article analyzes the Q3 earnings performance of Health Catalyst (NASDAQ:HCAT) against other data analytics stocks. While Health Catalyst showed softer revenue and missed guidance, other companies like Strategy (NASDAQ:MSTR), Domo (NASDAQ:DOMO), Samsara (NYSE:IOT), and Amplitude (NASDAQ:AMPL) had varying results, with Strategy outperforming expectations significantly despite market reaction. Overall, the data analytics sector saw strong Q3 revenues but experienced a significant decline in stock prices post-earnings.
Health Catalyst, Veeva Systems, 8x8, Amplitude, and DocuSign Stocks Trade Down, What You Need To Know
A number of tech stocks, including Health Catalyst, Veeva Systems, 8x8, Amplitude, and DocuSign, experienced declines due to concerns over Chinese restrictions on Nvidia's AI chips and deepening fears about a protectionist global economic environment. Additional market agitation stemmed from a Justice Department investigation into Fed Chair Jerome Powell and rising oil prices. Despite the broader market downturn, Veeva Systems had recently approved a significant share repurchase program, reflecting leadership confidence in the company's future.
Health Catalyst, Veeva Systems, 8x8, Amplitude, and DocuSign Shares Decline—Key Information You Should Be Aware Of
Several technology stocks including Health Catalyst, Veeva Systems, 8x8, Amplitude, and DocuSign experienced declines during afternoon trading due to a retreat in the tech sector, triggered by reports of Chinese customs stopping Nvidia's H200 AI chips and broader anxieties about global protectionism. Other factors contributing to market uncertainty included a Justice Department probe involving Federal Reserve Chair Jerome Powell and surging oil prices. Despite the broader market downturn, Veeva Systems, one of the affected companies, had recently announced a $2 billion share repurchase plan, signaling management's confidence in its long-term outlook.
A Quick Look at Today's Ratings for Health Catalyst(HCAT.US), With a Forecast Between $3 to $5
Major Wall Street analysts have updated their ratings for Health Catalyst (HCAT.US) on January 14, with price targets ranging from $3 to $5. Wells Fargo and William Blair analysts maintain "buy" ratings, while Evercore and Stifel analysts maintain "hold" ratings, with Stifel adjusting its target price slightly.
Health Catalyst stock reiterated as Buy at Stifel despite 2026 revenue guide
Stifel reiterated a Buy rating and a $3.75 price target for Health Catalyst Inc. (NASDAQ:HCAT), despite the company's mixed forward guidance and a projected 2-3% year-over-year revenue decline for 2026. The firm notes that while near-term catalysts are limited, Health Catalyst's efforts to reposition its business for growth, along with its current valuation and potential as an acquisition target, present opportunities for long-term investors. Health Catalyst's Q4 2025 results showed revenue slightly above consensus and EBITDA in line, with the company exceeding its net-new platform subscription client guidance for the year.
Health Catalyst stock reiterated as Buy at Stifel despite 2026 revenue guide By Investing.com
Stifel reiterated a Buy rating and a $3.75 price target for Health Catalyst (NASDAQ:HCAT), despite the company's mixed forward guidance, indicating the stock is significantly undervalued. Health Catalyst pre-released strong Q4 2025 results, exceeding client acquisition targets and aligning with EBITDA expectations, though its 2026 revenue guidance suggests a slight year-over-year decline. The analyst views Health Catalyst as a potential acquisition target with long-term growth opportunities, although short-term catalysts are limited.
Health Catalyst stock reiterated as Buy at Stifel despite 2026 revenue guide
Stifel reiterated a Buy rating and $3.75 price target for Health Catalyst (NASDAQ:HCAT), despite the company's 2026 revenue guidance indicating a slight year-over-year decline. The company's fourth-quarter 2025 results showed revenue slightly above consensus and EBITDA in line, with growth in new platform subscription clients. While near-term catalysts are limited, Stifel sees long-term potential in Health Catalyst's business repositioning and considers it a compelling acquisition target.
HCAT Projects Strong Client Growth and EBITDA Goals for FY25
Health Catalyst Inc. (HCAT) anticipates strong financial performance in fiscal year 2025, projecting an adjusted EBITDA of $41 million and exceeding its client acquisition goal by targeting 32 new platform clients. While the company demonstrates adequate liquidity and potential undervaluation based on P/S and P/B ratios, it faces significant risks including a negative Altman Z-Score, declining gross margins, and high volatility. Insider selling without corresponding buying also raises a red flag for investors.
Citi Maintains Health Catalyst(HCAT.US) With Hold Rating, Cuts Target Price to $2.75
Citi has reiterated a Hold rating on Health Catalyst (HCAT.US) while lowering its target price to $2.75. This indicates a cautious outlook from the analyst firm regarding the company's future stock performance.
HCAT: Citigroup Adjusts Price Target, Maintains Neutral Rating |
Citigroup has reaffirmed its "Neutral" rating for Health Catalyst (HCAT) but has lowered its price target by 15.38%, from $3.25 to $2.75. This adjustment follows a trend of declining price targets from various analysts for HCAT over recent months. Despite the lowered target, the average analyst target price of $3.94 still implies a 62.71% upside from the current price, with a consensus "Hold" status across brokerage firms.
HCAT: Citigroup Adjusts Price Target, Maintains Neutral Rating
Citigroup has maintained a "Neutral" rating for Health Catalyst (HCAT) but has lowered its price target by 15.38% from $3.25 to $2.75. This adjustment follows a trend of declining price targets from other firms like Wells Fargo, Stifel, Keybanc, and Evercore ISI Group in recent months. Despite these adjustments, the average target price from 8 analysts for HCAT is $3.94, suggesting an upside, and GuruFocus estimates a fair value of $6.40, indicating even greater potential upside.
Stifel Nicolaus Reaffirms Their Hold Rating on Health Catalyst (HCAT)
Stifel Nicolaus analyst David Grossman has maintained a Hold rating on Health Catalyst (HCAT) with a price target of $3.50. The company's recent Q3 earnings showed a slight decrease in revenue compared to the previous year and an increased GAAP net loss, alongside negative insider sentiment with increased selling activity. The analyst consensus on HCAT is a Moderate Buy with an average price target of $3.96.
HubSpot, nCino, Rapid7, and Health Catalyst Stocks Trade Down, What You Need To Know
Several tech stocks, including HubSpot, nCino, Rapid7, and Health Catalyst, experienced a downturn due to increasing investor concern that significant AI investments might not yield sufficient profits, sparking fears of an "AI bubble." This sentiment was exacerbated by Broadcom's warning about thinner profit margins from increased AI system sales, leading to a broader market recalibration and a shift away from speculative tech investments. Despite the general selloff, nCino had recently authorized a new $100 million stock repurchase program, signaling management's confidence in the company.
Health Catalyst (NASDAQ:HCAT) General Counsel Benjamin Landry Sells 27,425 Shares
Health Catalyst's General Counsel, Benjamin Landry, sold 27,425 shares of HCAT stock on December 5th at an average price of $2.64, reducing his holdings by over 21%. Following the sale, he directly owns 100,000 shares. HCAT shares are currently trading around $2.61, and analysts maintain a "Hold" rating with an average price target of $4.36 despite recent target cuts.
Health Catalyst (NASDAQ:HCAT) Director Sells $128,151.99 in Stock
Health Catalyst (NASDAQ:HCAT) Director Julie Larson-Green sold 47,997 shares of the company's stock, valued at $128,151.99, reducing her ownership by 39.48%. The company's stock traded down 1.1% to $2.61, and analysts currently have a "Hold" rating with an average target price of $4.36. Health Catalyst reported slightly better-than-expected quarterly earnings but remains unprofitable.
Health Catalyst's Market Cap Drops To US$190m Leaving Insiders With Losses
Health Catalyst's market capitalization has fallen to US$190 million after a 13% stock price decline, disappointing insiders who had invested US$895.1k at a higher average price. Despite these recent losses, the analysis of insider transactions suggests that Health Catalyst insiders remain optimistic about the company's future, with one director making a significant purchase above current prices. While insider ownership is not exceptionally high, the recent buying activity offers some confidence to investors looking at the company's prospects.
Health Catalyst's Market Cap Drops To US$190m Leaving Insiders With Losses
Health Catalyst's stock has declined by 13%, causing insiders who invested US$895.1k at an average price of US$2.95 to now face a loss, with their investment currently worth US$789.1k. Despite this, a significant purchase by Director Mathew Arens at a higher price than the current stock value suggests insider optimism for the company's future. The company's insiders own 4.6% of the company, valued at US$8.8m, suggesting some alignment with shareholder interests.
Health Catalyst's Market Cap Drops To US$190m Leaving Insiders With Losses
Health Catalyst, Inc.'s stock recently dropped by 13%, causing insiders who bought shares at an average of US$2.95 to experience losses, as their US$895.1k investment is now worth US$789.1k. The biggest insider purchase was made by Director Mathew Arens, who bought US$895k worth of shares at US$3.43 each, indicating prior optimism about the stock. Despite these recent losses, insider transactions suggest an expectation of a brighter future for Health Catalyst, though insider ownership remains relatively low at 4.6%.
Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Recommendation of "Hold" by Analysts
Health Catalyst, Inc. (NASDAQ:HCAT) has received an average "Hold" recommendation from analysts, with a consensus 12-month price target of $4.36. Despite recent rating cuts from some firms, UBS maintains an "outperform" rating. The company marginally beat Q3 earnings estimates but remains unprofitable, though institutional ownership is high at 85%.
Health Catalyst (Nasdaq: HCAT) appoints First Light CEO Matt Arens to board as 19% owner
Health Catalyst (Nasdaq: HCAT) announced that Matt Arens, CEO and founder of First Light Asset Management, has joined its board of directors, effective December 1, 2025. First Light and Arens collectively own approximately 19% of Health Catalyst's outstanding common stock. Arens' appointment is expected to provide valuable capital-markets expertise, particularly in the healthcare investment sector, to support strategic focus and shareholder value initiatives.
Health Catalyst appoints largest shareholder’s CEO to board
Health Catalyst Inc. (NASDAQ:HCAT) has appointed Matt Arens, CEO and Founder of First Light Asset Management, its largest shareholder, to its board of directors. Arens brings nearly three decades of investment experience, specializing in healthcare companies, and replaces Matthew Kolb who will not seek re-election. The company's shares have declined significantly year-to-date, but InvestingPro analysis suggests the stock is currently undervalued.
Health Catalyst Appoints New Board Member Matt Arens
Health Catalyst (HCAT) has appointed Matt Arens, CEO and Founder of First Light Asset Management, to its Board of Directors, expanding it to nine members. Arens will waive compensation for his board service. Concurrently, Matthew Kolb will not seek re-election, which will reduce the board back to eight members at the 2026 annual meeting.
Matt Arens, CEO and Founder of Health Catalyst's Largest Shareholder, First Light Asset Management, Joins Board of Directors
Health Catalyst, Inc. announced that Matt Arens, CEO and Founder of First Light Asset Management, LLC, has been appointed to its board of directors, effective December 1, 2025. First Light is Health Catalyst's largest shareholder, collectively owning approximately 19% of the company's outstanding shares. Mr. Arens' extensive experience in capital markets within the healthcare sector is expected to bring valuable insights to the board.
Health Catalyst to Participate in Upcoming Investor Conferences in Nashville and Miami
Health Catalyst, Inc. (Nasdaq: HCAT) announced its senior management will participate in several investor conferences in November and December 2025. These include fireside chats and 1x1 meetings at events such as The Stephens Annual Investment Conference, Canaccord Genuity MedTech Forum, and the Evercore and Citi Global Healthcare Conferences. The company, which provides data and analytics technology to over 1,100 healthcare organizations, aims to engage with stakeholders and highlight its leadership in improving healthcare outcomes.
Health Catalyst Achieves HITRUST r2 Certification, Demonstrating the Highest Level of Information Protection Assurance
Health Catalyst, a leading provider of data and analytics technology to healthcare organizations, announced that its Twistle, Lumeon, and Upfront solutions have achieved HITRUST r2 Certification for information security. This certification signifies that these offerings meet stringent regulatory compliance and industry-defined requirements for risk management. The achievement places Health Catalyst in an elite group of organizations worldwide and reinforces its commitment to safeguarding customer data, strengthening trust, and supporting healthcare organizations with highly reliable technology and services.
UnityPoint Health to Unlock Next Phase of Analytics Innovation by Activating Health Catalyst Ignite™
UnityPoint Health is transitioning to Health Catalyst's modern data platform, Health Catalyst Ignite™, after nine years of partnership. This move aims to enhance their data analytics capabilities, drive faster insights, and prepare them for future AI solutions, ultimately improving patient outcomes and operational efficiency. The upgrade will allow for more effective decision-making and scale the use of analytics across their integrated health system.
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
Health Catalyst, Inc. (NASDAQ:HCAT) has a low price-to-sales (P/S) ratio of 0.8x compared to the Healthcare Services industry average, which suggests investor caution. This low P/S is attributed to the company's underwhelming revenue growth, which has lagged behind its peers. Analysts forecast a modest 0.4% annual revenue increase for Health Catalyst over the next three years, significantly lower than the industry's projected 12% growth, thus justifying the current suppressed share price.
Health Catalyst, Twilio, Palantir Technologies, Zscaler, and Appian Shares Skyrocket, What You Need To Know
Shares of Health Catalyst, Twilio, Palantir Technologies, Zscaler, and Appian all saw significant jumps in the afternoon session after the Federal Reserve cut its benchmark interest rate by 25 basis points for the first time in 2025. This decision, influenced by signs of a weakening labor market, fueled optimism among investors, especially for tech stocks, despite initial concerns from the Fed's "dot plot" suggesting fewer cuts than the market had priced in. Lower interest rates are generally seen as positive for stocks as they reduce borrowing costs for businesses and make fixed-income investments less appealing.
